60834-87-9

Upstream product

• 33186-68-4 cyclopentyl phenyl ether 
• 211495-56-6 1-(3-(benzyloxy)phenyl)cyclopentanol 
• 1202643-77-3 C₁₇H₂₈OSi 

Downstream Products

• 530145-03-0 4-cyclopentyl-2-hydroxybenzaldehyde 

Relevant academic research and scientific papers

HCV POLYMERASE INHIBITORS

The invention provides compounds of the formula:wherein B is a nucleobase selected from the groups (a) to (d):and the other variables are as defined in the claims, which are of use in the treatment or prophylaxis of hepatitis C virus infection, and related aspects.

DIOXOLANE ANALOGUES OF URIDINE FOR THE TREATMENT OF CANCER

The invention provides compounds of formula (I), wherein: R1 is OR11, or NR5R5'; R2 is H or F; R5 is H, C1-C6alkyl, OH, C(=O)R6, O(C=O)R6 or O(C=O)OR6; R5′ is H or C1-C6alkyl; R6 is C1-C6alkyl or C3-C7cycloalkyl; R13 is H, phenyl, pyridyl, benzyl, indolyl or naphthyl wherein the phenyl, pyridyl, benzyl, indolyl and naphthyl is optionally substituted with 1, 2 or 3 R22; and the other variables are as defined in the claims, which are of use in the treatment of cancer, and related aspects.

HCV POLYMERASE INHIBITORS

The invention provides compounds of the formula:(I) wherein B is a nucleobase selected from the groups (a) to (d) and the other variables are as defined in the claims, which are of use in the treatment or prophylaxis of hepatitis C virus infection, and related aspects.

HCV POLYMERASE INHIBITORS

The invention provides compounds of the formula (I) wherein B is a nucleobase selected from the groups (a) to (d): and the other variables are as defined in the claims, which are of use in the treatment or prophylaxis of hepatitis C virus infection, and related aspects.

NOVEL COMPOUNDS, ISOMER THEREOF, OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF AS VANILLOID RECEPTOR ANTAGONIST AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME

This present invention relates to novel compounds, isomer thereof or pharmaceutically acceptable salts thereof as vanilloid receptor (Vanilloid Receptor 1; VR1; TRPV1) antagonist; and a pharmaceutical composition containing the same. The present invention provides a pharmaceutical composition for preventing or treating a disease such as pain, migraine, arthralgia, neuralgia, neuropathies, nerve injury, skin disorder, urinary bladder hypersensitiveness, irritable bowel syndrome, fecal urgency, a respiratory disorder, irritation of skin, eye or mucous membrane, stomach-duodenal ulcer, inflammatory diseases, ear disease, heart disease and so on.

NOVEL BENSOPHENONE DERIVATIVES OR SALTS THEREOF

A benzophenone derivative represented by the following formula: whereinR1 represents, for example, an optionally substituted heterocyclic group, or a substituted phenyl group; Z represents, for example, an alkylene group; R2 represents, for example, a carboxyl group optionally protected with alkyl;R3 represents, for example, an optionally protected hydroxyl group; R4 represents, for example, an optionally substituted cycloalkyloxy group; and R5 represents, for example, a hydrogen atom, ???or a salt thereof has anti-arthritic activity, inhibits bone destruction caused by arthritis, and provides high safety and excellent pharmacokinetics and thus is useful as therapeutic agent for arthritis. These compounds have inhibitory effect on AP-1 activity and are useful as preventive or therapeutic agent for diseases in which excessive expression of AP-1 is involved.

2-AMINO-6-(2-SUBSTITUTED-4-PHENOXY)-SUBSTITUTED-PYRIDINES

This present invention relates to compounds of the formula wherein G, R1 and R2 are defined as in the specification, to pharmaceutical compositions containing them and to their use in the treatment and prevention of central nervous system and other disorders.

Acid-Catalyzed Hydrolysis of Some Secondary Alkyl Phenyl Ethers in Perchloric Acid: Kinetics and Mechanism

Hydrolysis rates and products of isopropyl, cyclopentyl and cyclohexyl phenyl ethers were studied in concentrated aqueous perchloric acid solutions.The activation parameters, solvent deuterium isotope effects, dependences of the reaction rates on acid concentration, substituent effects and products were in agreement with the A-1 mechanism.The pKSH+ values (-6.13 to -5.76) and the slope parameters m* (av. 0.98 +/- 0.03) were measured spectrophotometrically by the excess acidity method.They were used to calculate the m++-parameters (1.46-2.01).Comparisons weremade with the hydrolyses of exo- ad endo-2-norbornyl phenyl ethers and secondary alyl methanesulfonates.

Preparation of diphenolics

A process for the production of diphenolic compounds having a divalent bridge. A first disubstituted phenol is reacted with an aldehyde in the presence of a secondary amine and excess alcohol to form an ether intermediate. The ether intermediate is reacted with a phenol having an open ortho or para position to form a diphenolic.